#CINPonline

SECOND ANNOUNCEMENT

CINP 2021
VIRTUAL
WORLD CONGRESS
26 - 28 February 2021

Connect virtually with global experts in neuropsychopharmacology

Welcome Message

Dear All,

After close monitoring of the global risk assessment by the World Health Organization of the COVID-19 pandemic, we wish to share with you today on behalf of the CINP Executive Committee that the 32nd World Congress of Neuropsychopharmacology, rescheduled to 25 – 28 February 2021 in Taipei, Taiwan will now take place online as a fully virtual congress.

It is our top priority to care for the health and welfare of our participants. We are aware of the travel restrictions that are being changed on a daily basis and impacting our colleagues' ability to attend the conferences. We also are aware that health institutions, organisations and educational institutions are restricting employee and student travel and participation in upcoming conferences, and that public health bodies do not allow events to proceed as normal at this stage.

Please note that your registration fees from the rescheduled in-person congress can be transferred to the new virtual format of the CINP World Congress, now taking place on 26 – 28 February 2021. For those who prefer, registration fees will be reimbursed. For more information please refer to **www.cinp2020.org/congress-faqs**

We look forward to bringing this new format of the congress to you virtually. Please stay tuned for more exciting announcements! We will return to Taipei in June 2022 for the 34th World Congress of Neuropsychopharmacology.

In the meantime, please stay safe and healthy.

On behalf of the CINP Executive Committee,

Siegfried Kasper
CINP President

About CINP

The International College of Neuropsychopharmacology (CINP) is a truly worldwide organization established over 50 years ago in Zurich, Switzerland. CINP holds meetings all over the world with the aim to promote research and education on a worldwide basis. With the change to go annual with the CINP World Congress, the college will also focus more on smaller seminars and workshops in between.

The Executive Committee and Councilors of CINP are nominated by the membership and serve as officers of the College for a minimum of 4 years. These individuals cover a wide range of disciplines within the field, from psychiatrists, psychopharmacologists, basic and clinical researchers to clinical psychologists. CINP also relies on its many subcommittees which undertake a variety of activities for the College.

Membership of the College is available to any individual to apply for and we offer members the opportunity to become part of this knowledgeable group of scientists who work at an international level. The membership application is reviewed by a dedicated committee on a regular basis and applications can be made online. As a member of CINP you may have the opportunity to be invited to one of the smaller meetings or invited to participate in the running of the College by sitting on a subcommittee.

CINP 2020/21 Committees

Executive Committee

CINP President
Kasper, Siegfried, Austria

CINP Past President
Krystal, John H., USA

CINP President Elect
Blier, Pierre, Canada

CINP Vice President
Lin, Shih-Ku, Taiwan

CINP Vice President
Zohar, Joseph, Israel

CINP Secretary
Eriksson, Elias, Sweden

CINP Treasurer
Ikeda, Kazutaka, Japan

Councillors

Calil, Helena, Brazil
Domschke, Katharina, Germany
Falkai, Peter, Germany
Fava, Maurizio, USA
Gobbi, Gabriella, Canada
Hashimoto, Ryota, Japan
Kwon, Jun Soo, Republic of Korea
Nitta, Atsumi, Japan
Tamminga, Carol, USA
Young, Allan, United Kingdom

International Scientific Programme Committee

Chair
Blier, Pierre, Canada

Co-chair
Eriksson, Elias, Sweden

Co-chair
Osumi, Noriko, Japan

Chiou, Lih-Chu, Taiwan
Cryan, John, Ireland
Domschke, Katharina, Germany
Falkai, Peter, Germany
Fountoulakis, Kostas, Greece
Frazer, Alan, USA
Gobbi, Gabriella, Canada
Huang, Ming-Chyi, Taiwan
Hiroi, Noboru, USA
Ikeda, Kazutaka, Japan
Kasper, Siegfried, Austria
Kwon, Jun Soo, Korea
Krystal, John, USA
Lanzenberger, Rupert, Austria
Lin, Shih-Ku, Taiwan
McGuire, Philip, UK
Morilak, David, USA
Shamay-Tsoory, Simone, Israel
Soldatos, Constantin, Greece
Tamminga, Carol, USA
Uchida, Hiroyuki, Japan
Yamawaki, Shigeto, Japan
Zohar, Joseph, Israel

South Asia & South-East Asia Committee (SASEAC)

Co-chair
Yang, Yen-Kuang, Taiwan

Co-chair
Chen, Po-See, Taiwan

Guan, Ng Chong, Malaysia
Heok, Kua Ee, Singapore
Karimah, Azimatul, Indonesia
Lam, Tu Trung, Vietnam
Liaury, Kristian, Indonesia
Savuon, Kim, Cambodia
Sirithongthaworm, Samai, Thailand
Tanra, Andi J., Indonesia
Thanh, Dang Duy, Vietnam
Wiguna, Tjhin, Indonesia

AsCNP Committee

Chair
Ikeda, Kazutaka, AsCNP President, Japan

Co-chair
Tan, Chay Hoon, AsCNP President-Elect, Singapore

Co-chair
Tanra, Andi J., AsCNP Past President, Indonesia

Nitta, Atsumi, Japan
Kim, Chan Hyung, Korea
Lee, Sangyeol, Korea
Yamawaki, Shigeto, Japan
Lin, Shih-Ku, Taiwan
Sundram, Suresh, Australia
Si, Tianmei, China
Chung, Young Chul, Korea

New Executive Committee after Virtual World Congress 2021

CINP President
Blier, Pierre, Canada

CINP Past President
Kasper, Siegfried, Austria

CINP President Elect
Zohar, Joseph, Israel

CINP Vice President
Lin, Shih-Ku, Taiwan

CINP Vice President
Oquendo, Maria, USA

CINP Secretary
Gobbi, Gabriella, Canada

CINP Treasurer
Ikeda, Kazutaka, Japan

New Councillors after Virtual World Congress 2021

Domschke, Katharina, Germany
Falkai, Peter, Germany
Hashimoto, Ryota, Japan
Hiroi, Noboru, USA
Huang, Ming-Chyi, Taiwan
Nitta, Atsumi, Japan
Si, Tian Mei, China
Tamminga, Carol, USA
Young, Allan, United Kingdom
Zarate, Carlos, USA

Programme at a Glance

DAY 1 – Friday 26 February 2021

All times in CET (Central European Time)

07:45 – 08:30	**Opening Session and Awards**		
08:30 – 09:30	**Plenary Lecture:** Chair: **Shih-Ku Lin**, Taiwan and **Rupert Lanzenberger**, Austria From Genes to Clinical Phenotype in ADHD Across the Lifespan **Barbara Franke**, Radboud University, The Netherlands		
09:30 – 10:00	Break		
10:00 – 11:00	**Industry Symposium**		
11:00 – 11:30	Break		
11:30 – 12:40	**Symposium 1:** Transgender Hormone Therapy: Effects on Brain Structure and Function Chair: **Eileen Luders**, New Zealand and **Masanari Itokawa**, Japan **1. Hormonal Treatment Effects on the Brain: Findings From the Enigma Transgender Persons Working Group** **Sven C. Müller**, Belgium **2. Sex Matters – A Multivariate Pattern Analysis of Sex and Gender** **Pia Baldinger-Melich**, Austria **3. Effects of Sex Hormones on Serotonergic Neurotransmission** **Georg S. Kranz**, Hong Kong **4. A New Theory About the Neurobiology of Gender Dysphoria** **Sarah M. Burke**, The Netherlands	**Symposium 2:** The Importance of the Muscarinic M1 Receptor in CNS Function and as a Drug Target Chair: **Brian Dean**, Australia and **Wen-Sung Lai**, Taiwan **1. Evidence Suggesting the Muscarinic M1 Receptor Has a Role in the Aetiology and Treatment of Schizophrenia** **Brian Dean**, Australia **2. The Role of CHRM1 Signalling in Cognitive and Behavioural Symptoms of Psychosis** **Geor Bakker**, The Netherlands **3. Systems Biology of Mammalian Sleep/Wake Cycles: The Roles of Muscarinic Acetylcholine Receptor in NREM and REM Sleep** **Hiroki Ueda**, Japan **4. The Muscarinic M1 Receptor in CNS Function and as a Drug Target for Slowing the Progression of Neurodegenerative Disease** **Andrew Tobin**, UK	**Mandarin Session 1**
12:40 - 13:00	Break		

Programme at a Glance

DAY 1 – Friday 26 February 2021

All times in CET (Central European Time)

13:00 – 14:15	**The Selected Ones (Oral Abstracts)** Chair: **Noriko Osumi**, Japan and **Yen-Kuang Yang**, Taiwan **1. Cannabinoid Receptor Genetics: From Genes to Behavior and Neuro-Immune Crosstalk in Depression and Schizophrenia** E.Onaivi[1], **Hiroki Ishiguro[2]**, Y. Horiuchi[3], Q.-R. Liu[4] [1]William Paterson University, USA, [2]University of Yamanashi, Japan, [3]Tokyo Metropolitan Institute, Japan, [4]NIA-IRP/NIH, USA **2. Cerebral Volumetric Correlates of ADHD Trait and Their Heritability: A Voxel-Based Morphometry Study of the ABCD Data** **Chiang-Shan Li**, Yale University School of Medicine, USA **3. Prominent Memory Deficits and Brain Beta-Amyloid Deposits in Elderly Treatment-Resistant Depression** **Hsuan Lee[1]**, J.S. Jeng[1], T.P. Su[2], Y.M. Bai[1,2], C.M. Cheng[1], C.T. Li[1,2,3] [1]Taipei Veterans General Hospital, Taiwan, [2]School of Medicine, National Yang-Ming University, Taiwan, [3]National Central University, Taiwan **4. Polygenetic Risk Scores for Major Psychiatric Disorders Among Schizophrenia Patients, Their First-Degree Relatives and Healthy Subjects** **Kazutaka Ohi[1]**, D. Nishizawa[2], T. Shimada[3], Y. Kataoka[3], J. Hasegawa[2], T. Shioiri[1], Y. Kawasaki[3], R. Hashimoto[4], K. Ikeda[2] [1]Gifu University Graduate School of Medicine, Japan, [2]Tokyo Metropolitan Institute of Medical Science, Japan, [3]Kanazawa Medical University, Japan, [4]National Center of Neurology and Psychiatry, Japan **5. The Differential Pattern of Functional and Structural Connectivity of Frontostriatal Circuits Between Methamphetamine Users with and without Persistent Psychosis in Comparison to Patients with Schizophrenia** **Ming-Chyi Huang**, C.-W. Li, W. Chen Taipei Medical University, Taiwan **6. The Impact of Sex Hormones and Hormonal Contraception on d-Amphetamine-Induced Dopamine Release: A [11C]-(+)-PHNO Study in Healthy Female Subjects** **Ana Weidenauer**, U. Sauerzopf, I. Graf, M. Bauer, L. Bartova, C. Philippe, N. Berrotéran-Infante, V. Pichler, M. Mitterhauser, W. Wadsak, R. Lanzenberger, S. Kasper, N. Praschak-Rieder, M. Willeit Medical University of Vienna Department of Psychiatry and Psychotherapy, Austria	**Clinical Focus and Frontiers: OCD** Chair: **Tian Mei Si**, China and **Konstantinos Fountoulakis**, Greece **1. Diagnosis** **Joseph Zohar**, Israel **2. Therapeutics** **Naomi Fineberg**, UK	

Programme at a Glance

DAY 1 – Friday 26 February 2021

All times in CET (Central European Time)

14:15 – 14:30	Break		
14:30 – 15:30	**Industry Symposium: Sumitomo Dainippon**		
15:30 – 16:00	Break		
16:00 – 17:10	**Symposium 3:** Partial Dopamine Agonists: Wide Spectrum Medications for Psychiatric Disorders Chair: **Steven Potkin**, USA and **Tetsuro Kikuchi**, Japan **1. Pharmacological and Physiological Profiles of Aripiprazole, Brexpiprazole, and Cariprazine** **Pierre Blier**, Canada **2. Clinical Effects of Long-Acting Injectable Aripiprazole in Schizophrenia** **Steven Potkin**, USA **3. The Role of Brexpiprazole in the Treatment of Inadequate Response in Major Depressive Disorder** **Diane McIntosh**, Canada **4. Broad Spectrum Efficacy of Cariprazine in the Management of Bipolar Disorder** **Lakshmi Yatham**, Canada	**Symposium 4:** Altered Circadian Rhythms in Psychiatric Mood Disorders: New Treatment Strategies Chair: **William E. Bunney**, USA and **Po-Hsiu Kuo**, Taiwan **1. Strengthening of Circadian Rhythm Amplitude Stabilizes and Improves Mood: Evidence from Animal Models** **Colleen A. McClung**, USA **2. Abnormal Core Clock Genes in MDD: Potential Resetting with Rapid-Acting Antidepressants** **William E. Bunney**, USA **3. Adjustment of Central and Peripheral Circadian Clocks in Humans** **Diane B. Boivin**, Canada **4. Light Signaling Alterations and Light Use in Depression** **Pierre A. Geoffroy**, France	
17:10 – 17:30	Break		
17:30 – 18:30	**Plenary Lecture:** Chair: **Siegfried Kasper**, Austria and **John Krystal**, USA ACE2 – From Discovery to the Centre of a Pandemic **Josef Penninger**, Life Sciences Institute, UBC, Canada		

Programme at a Glance

DAY 2 – Saturday 27 February 2021

All times in CET (Central European Time)

08:30 – 09:30	**Plenary Lecture:** Chair: **Winston Shen**, Taiwan and **Toshi A. Furukawa**, Japan Big Data Analyses for Neuropsychopharmacology **Tung-Ping Su**, Cheng-Hsin General Hospital, Taiwan		
09:30 – 10:00	Break		
10:00 – 11:00	**Industry Symposium: Janssen**		
11:00 – 11:30	Break		
11:30 – 12:40	**Symposium 5:** Stronger Together? Using PET and MRI in Neuropsychopharmacology Chair: **David Nutt**, UK and **Rupert Lanzenberger**, Austria **1. 5-HT Reuptake Site, 5-HT1A Receptors, and the Neuroimaging Revolution with Functional PET Providing High Temporal Resolution** **Rupert Lanzenberger**, Austria **2. Mu-opioid Receptor Availability and Functional Connectivity During Reward Processing in Gambling Disorder** **Chen-Chia Lan**, Taiwan **3. Dopamine D2 Receptors: Simultaneous PET Measures and fMRI Signals** **Christin Sander**, USA **4. 5-HT2A Receptor PET, Serotonin Release and Amygdala fMRI Responses in Depression** **David Nutt**, UK	**Symposium 6:** Treatment Resistant Depression Chair: **Siegfried Kasper**, Austria and **Kuan-Pin Su**, Taiwan **1. Characterization of Treatment Resistant Depression in Europe** **Siegfried Kasper**, Austria **2. Genetic Findings in TRD** **Chiara Fabbri**, Italy **3. Glutamateric Approach in TRD** **Carlos Zarate**, USA **4. Deep Brain Stimulation in TRD** **Thomas Schläpfer**, Germany	**Mandarin Session 2**
12:40 - 13:00	Break		

Programme at a Glance

DAY 2 – Saturday 27 February 2021

All times in CET (Central European Time)

13:00 – 14:15	**Rafaelsen Symposium** Chair: **Elias Eriksson**, Sweden and **Pierre Blier**, Canada **1. The Clinical Impact of Melancholic Features in Major Depressive Disorder – Results From a Cross-Sectional European Multicenter Study** **Lucie Bartova**[1], M. Dold[1], G. Fugger[1], A. Kautzky[1], A. Weidenauer[1], U. Sauerzopf[1], M. Mitschek[1], R. Frey[1], C. Fabbri[2], S. Montgomery[3], J. Zohar[4], D. Souery[5], J. Mendlewicz[5], A. Serretti[2], S. Kasper[1] [1]Medical University of Vienna, Austria, [2]University of Bologna, Italy, [3]Imperial College, UK, [4]Chaim Sheba Medical Center, Israel, [5]Université Libre de Bruxelles and Psy Pluriel, Centre Européen de Psychologie Médicale, Belgium **2. Investigating the Role of Genes Encoding the Fatty Acid Amide Hydrolase (FAAH) and Monoacylglyercide Lipase (MAGL) Enzymes in Emotional Processing in Adolescents** **Chandni Hindocha**[1], H. Irizar[1], G. Schumann[2]; [1]University College London, UK, [2]King's College London, UK **3. Early Pup Removal Precipitates a Depressive-Like State and Dopamine Deficit in Postpartum Rats: Amelioration by Social Support** **Millie Rincon Cortes**, A. Grace University of Pittsburgh, USA **4. Translating Gene Networks into Treatments for Alzheimer's Disease** **Zachary Gerring**[1], E. Gamazon[2], A. White[1], E. Derks[1] [1]QIMR Berghofer Medical Research Institute, Australia, [2]Vanderbilt Genetics Institute, USA **5. Meta-Analysis of Gray Matter Volume Changes After Electroconvulsive Therapy in Depression – An Update** **Pia Baldinger-Melich**, G. Gryglewski, S. Kasper, R. Frey, R. Lanzenberger Medical University of Vienna, Austria **6. Computational Drug Repositioning for Psychiatric Disorders** **Hon-Cheong So**, The Chinese University of Hong Kong, Hong Kong	**Clinical Focus and Frontiers: ADHD** Chair: **Joseph Zohar**, Israel and **Gabriella Gobbi**, Canada **1. Neurobiological Research in ADHD – Opportunities for Personized Medicine?** **Barbara Franke**, The Netherlands **2. TBC** **Larry Klassen**, Canada	

Programme at a Glance

DAY 2 – Saturday 27 February 2021

All times in CET (Central European Time)

14:15 – 14:30	Break		
14:30 – 15:30	**Industry Symposium: Sumitomo Dainippon**		
15:30 – 16:00	Break		
16:00 – 17:10	**Symposium 7:** Rapid Onset and Sustained Action of Ketamine in Depressive Episodes: From the Laboratory to the Community Chair: **Pierre Blier**, Canada and **Cheng-Ta Li**, Taiwan **1. Impact of Ketamine on the Intracellular Signaling Beyond the N-methyl-D-aspartate Receptors** **Lisa Monteggia**, USA **2. Neural Networks Involved in the Action of Ketamine** **Carlos Zarate**, USA **3. Impact of Intravenous Ketamine on Depression and Suicidal Ideation** **Jennifer Phillips**, Canada **4. The Use of Ketamine in Clinical Practice: Data Set From 6,000 Community Patients** **Steve Levine**, USA	**Symposium 8:** Gene-Environment Interaction in Schizophrenia: Genetic Load Modulates the Deleterious Impact of Stressors to Lead to the Emergence of Psychosis Chair: **Anthony Grace**, USA and **Chih-Ken Chen**, Taiwan **1. Cannabis-Associated Psychosis; Mechanisms and Implications** **Robin Murray**, UK **2. The Neuroimmune Hypothesis of Schizophrenia and Cannabis Use Relevance in Youth - Novel Studies with TSPO PET** **Romina Mizrahi**, Canada **3. Inability to Regulate Stress Prepubertally as a Risk Factor for Schizphrenia: Disregulation of Prefrontal-Amygdala-Hippocampal Circuitry** **Anthony Grace**, USA **4. A Convergent Circuit for Genetic and Environmental Risk for Schizophrenia** **Andreas Meyer-Lindenberg**, Germany	
17:10 – 17:30	Break		
17:30 – 18:30	**Plenary Lecture:** Chair: **Elias Eriksson**, Sweden and **Pierre Blier**, Canada Neurobiological and Physiological Consequences of Social Isolation: A Portal to Psychopathology **Maria Oquendo**, University of Pennsylvania, USA		

Programme at a Glance

DAY 3 – Sunday 28 February 2021

All times in CET (Central European Time)

08:30 – 09:30	**Plenary Lecture:** Chair: **Kazutaka Ikeda**, Japan and **Susan Gau**, Taiwan Transgenerational Epigenetics: A Key to Understand Neurodevelopmental Diseases **Noriko Osumi**, Tohoku University, Japan		
09:30 – 10:00	Break		
10:00 – 11:00	**Industry Symposium: Lundbeck - tentative**		
11:00 – 11:30	Break		
11:30 – 12:30	**Debate:** Chair: **John Krystal**, USA and **Ming-Chyi Huang**, Taiwan Is Long-Term Treatment with Antipsychotics Justified? **Konstantinos Fountoulakis**, Greece vs. **Robin Murray**, UK		11:30 - 12:40 **Mandarin Session 3**
12:30 – 13:00	Break		
13:00 – 14:10	**Symposium 9:** Estrogen and Psychiatric Illnesses Chair: **Mark Weiser**, Israel and **Chia-Yih Liu**, Taiwan **1. Aromatase in the Brain and Human Personality** **Kayo Takahashi**, Japan **2. Circuit and Cellular Substrates of the Differential Behavioral Response to Ovarian Steroids in Women with Reproductive Endocrine-Related Mood Disorders** **Peter Schmidt**, USA **3. Prenatal Steroid Hormones and Autistic Traits in Expectant Mothers and Their Children** **Alexandros Tsompanidis**, UK **4. Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Controlled Trial** **Mark Weiser**, Israel	**Symposium 10:** Novel Molecular and Cellular Mechanisms of Rapid-acting Antidepressant Ketamine and Its Enantiomers Chair: **Kenji Hashimoto**, Japan and **Hwei-Hsien**, Taiwan **1. Antidepressant Mechanisms of Prefrontal Theta-Burst Stimulation (TBS) : A Ketamine-Responsive Animal Model of SSRI-Resistant Depression** **Cheng-Ta Li**, Taiwan **2. Role of Immune System in Rapid-Acting and Long-Lasting Antidepressant Effects of Ketamine** **Kai Zhang**, China **3. Molecular Mechanisms Underlying Rapid-Acting and Long-Lasting Antidepressant Effects of Ketamine** **Kenji Hashimoto**, Japan **4. TBC** **Lucas Quarantini**, Brazil	
14:10 – 14:30	Break		
14:30 – 15:30	**Plenary Lecture:** Chair: **Joseph Zohar**, Israel and **Yen-Kuang Yang**, Taiwan Effects of Cannabis in Adolescence and Depression Risk in Young Adulthood: From Animals to Human Studies **Gabriella Gobbi**, McGill University, Canada		

Plenary Speakers

Barbara Franke

Radboud University, The Netherlands

Barbara Franke, PhD is professor of Molecular Psychiatry at Radboud University in Nijmegen, The Netherlands, where she is based at the Human Genetics and Psychiatry departments of the Radboud UMC. Her research is focused on understanding the genetic contribution to neurodevelopmental psychiatric disorders, especially ADHD and its comorbidities.

Gabriella Gobbi

McGill University, Canada

Dr. Gabriella Gobbi is a Professor in the Department of Psychiatry, McGill University. She leads a laboratory of basic science (Neurobiological Psychiatry Unit) and works as a Staff Psychiatrist at the Mood Disorder Clinic of the McGill University Health Center. Her research approach spans from bench to bedside, bridging the gaps between fundamental and clinical research. Dr. Gobbi received her MD (1991) and her specialty in Psychiatry and Psychotherapy (1995) from the Catholic University of Rome (Italy). She also earned a PhD in Neuroscience at the University of Cagliari, Italy) and finalized a post-doc at McGill University (Montreal, Canada) in 1998. Dr Gobbi's lab is interested in understanding the pathophysiology of major depression and sleep related disorders and in the discovery of new treatments and cures for them. In particular, her laboratory is studying the short- and long-term effects of cannabis use in mood and anxiety, and the potential beneficial effects of the drugs acting on the endocannabinoid system (endogenous cannabis) in the cure of mental diseases. Her lab is also studying the effect of melatonin in mood, anxiety and sleep regulation in an effort to understand how novel selective ligands for melatonin receptors (called MT1 and MT2 receptors) can be used to treat seasonal depression, major depression, sleep disorders, as well as pain. Dr. Gobbi is author of more than 90 highly cited manuscripts in high impact journals, 20 book chapters, one book and holds two international patents in psychopharmacology. She has received several fellowships for more than $10M as a principal investigator. She has won many prizes including the Canadian College of Neuropsychopharmacology (CCNP) Young investigator Award in 2012, the Venezia Prize in 2015 and the Sam Lal prize from the Boeckh Foundation in 2017. She has served as reviewer/editor for many journals, international grant agencies in Europe and the USA and has been invited to speak at conferences around the world.

Maria Oquendo

University of Pennsylvania, United States

Maria A. Oquendo, MD, PhD is Ruth Meltzer Professor and Chairman of Psychiatry, University of Pennsylvania. She has used Positron Emission Tomography to map brain abnormalities in mood disorders and suicidal behavior. Her expertise ranges from psychopharmacology to Global Mental Health with over 450 publications.

Professor Oquendo is President of American College of Neuropsychopharmacology (ACNP), American Foundation for Suicide Prevention, past President of the American Psychiatric Association, CINP's Vice-President Elect, and a National Academy of Medicine member, one of the highest honors in medicine.

A recipient of multiple international awards, most recently, she received the Dolores Shockley Award (ACNP, 2018).

Plenary Speakers

Noriko Osumi

Tohoku University, Japan

Prof. Osumi has graduated Tokyo Medical and Dental University, been given PhD thesis from the same university, and now is a professor of Tohoku University School of Medicine since 1998. She is appointed in various governmental committees such as ethical issues, grant system development, and career paths for young scientists, and also chosen as a youngest member of Japanese Council Japan since 2005. Her research interest covers broad areas such as pre- and postnatal development of the brain and craniofacial region, and behavior of animals as models of psychiatric diseases. More specifically, she is recently eager to understand regulatory mechanisms of neurogenesis and maintenance of neural stem cells at cellular and molecular levels both in embryonic and postnatal stages. Manipulating embryos and imaging brain cells are expertise of her lab.

Josef Penninger

Life Sciences Institute, UBC, Canada

Josef Penninger, MD was formerly a lead researcher at the Amgen Research Institute in Toronto. Since 2002 he was the founding and scientific director of the newly established Institute of Molecular Biotechnology in Austria. 2018 he accepted the appointment as Director of the Life Sciences Institute at the University of British Columbia in Canada.

Tung-Ping Su

Cheng-Hsin General Hospital, Taiwan

Professor Tung-Ping Su is the chair of the Department of Psychiatry, Cheng-Hsin General Hospital and Professor Emeritus of National Yang-Ming University, Taipei, Taiwan. Dr. Su was the previous president of AsCNP. His interests are studying mood disorders and brain imaging. Dr. Su is one of the pioneers conducting clinical trials on ketamine and depression in the Asian populations and is the recipient of the “Academic Achievement Award” from the Taiwanese Society of Psychiatry.

Debate Speakers

Konstantinos Fountaoulakis,
Aristotle University of Thessaloniki, Greece

Konstantinos N. Fountoulakis, MD, is Professor of Psychiatry at Aristotle University of Thessaloniki, AHEPA University Hospital, in Thessaloniki, Greece. He has coauthored more than 400 papers and more than 250 of them are published in high impact international journals with approx. 10,000 citations and h=50 (Publish or Perish). During the years 2016-8, he was ranked by expertscape.com within the top 25 world experts concerning Bipolar disorder (0.068%) and among the top 50 concerning suicidality (0.097%). He authored or co-authored a number of chapters in books, the book 'Bipolar disorders: An Evidence-Based Guide to Manic Depression' (Springer-Verlag 2015), co-edited the WPA book 'Advances in Psychiatry vol 3' (Springer-Verlag 2018), and the book 'Psychobiology of behavior' (Springer-Verlag 2019). He has received a number of national and international research awards, including the 2012 Kraepelin-Alzheimer medal of the University of Munich and the 2015 Excellence in Education Award of the WFSBP. Since 2014, he has been an honorary member of the WPA.

Robin Murray,
King's College, United Kingdom

Robin Murray is Professor of Psychiatric Research at the Institute of Psychiatry, London. He was one of the first to suggest that schizophrenia was in part a neurodevelopmental disorder, and he has contributed to the understanding that environmental factors such as obstetric events, drug abuse and social adversity increase the risk of psychosis. He is the most frequently cited psychosis researcher outside the USA, has supervised 72 PhDs and 12 MD Theses, and 40 of his students have become full professors. He was elected a Fellow of the Royal Society in 2010 and received a knighthood in 2011.

CINP 2020/21 Awardees

Pioneer Awards

Oleh Hornykiewicz

Oleh Hornykiewicz was born on November 17, 1926 in Sychiw near Lviv/Lemberg in Eastern Galicia today belonging to the western part of Ukraine and died on May 26, 2020. He received his M.D. degree from the University of Vienna and joined the faculty of his alma mater the same year and has worked there ever since. He also served for twenty years as chairman of the Institute of Biochemical Pharmacology. In 1967, he began a long association with the University of Toronto in Canada and, in 1992, he was named professor emeritus at that institution.

One of his seminal accomplishments was the discovery that Parkinson's disease was due to dopamine deficiency in the brain. He also played a key role in the development of L-dopa as a therapy for the disorder.

After the integration of the Institute of Biochemical Pharmacology into the Brain Research Institute of the University of Vienna in 1999, he spent ,up to three years ago, all days at his office at the Brain Research Institute, now Center for Brain Research of the Medical University of Vienna. He vividly and highly scholarly discussed his ideas on rather different topics in neuroscience. His favorite topic however still remained basal ganglia and Parkinson´s disease.

Judith Rapoport

Dr. Judith Rapoport has concentrated her research on several aspects of child psychiatry, including diagnosis, childhood hyperactivity, pediatric psychopharmacology, and obsessive-compulsive disorder. Her current research on attention deficit hyperactivity disorder has focused on normal and abnormal brain development.

Dr. Rapoport was named chief of the Child Psychiatry Branch of the National Institute of Mental Health in 1984. In addition to her research at NIH, she is also a professor of psychiatry at George Washington University School of Medicine, and a clinical professor of psychiatry and pediatrics at Georgetown University Medical School.

Dr. Rapoport has authored and coauthored three professional books and over two hundred research journal articles. She also serves on the editorial board of Advances in Clinical Child Psychiatry, American Journal of Psychiatry, and Journal of Child Psychology and Psychiatry, among others.
Among her many honors are several awards including the G. Burroughs Mider Lecture, NIH, in 1993, the American Psychiatric Association Award for Research in 1992, the Presidential Meritorious Executive Rank Award in 1991, and the NIMH Director's Award in 1990.

Torgny Svenson

Torgny Svenson, Professor emeritus of Pharmacology at Karolinska Institutet, succumbed to Covid-19 on Friday June 12, 2020, at the age of 75. He is grieved by his wife Louise and their children Martin, Jenny and Michael, and missed by many friends and colleagues in Sweden and around the world.

During Torgny's period as a very successful president of the Scandinavian College of Neuropsychopharmacology (SCNP) from 2001 to 2005, the annual meetings of this society attracted more attendants than ever before. Illustrating his standing in the international psychopharmacological sphere, he became President of the CINP in 2006, and held this position when the society celebrated its 50 years anniversary. Torgny was a person whom you did not easily forget, if you had had the privilege to meet him on a person-to-person basis. He was a great scientist always ready to discuss experiments and his most novel ideas in detail, and he inspired and guided a large number of PhD students through their journey to a successful defense.

CINP 2020/21 Awardees

Sumitomo/Sunovion Brain Health Basic Research Award

Tibor Harkany

Dr. Tibor Harkany is Professor at the Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden and Chair of the Department of Molecular Neurosciences, Center for Brain Research, Medical University of Vienna, Austria.

He is one of the world's leading neurobiologists to study the developmental consequences of maternal drug abuse during pregnancy, with a keen focus on cannabis and psychostimulants. His work on the molecular basis of how Δ9-tetrahydrocannabinol (THC) impacts brain development and imposes life-long modifications to the cortical circuitry is particularly honored by this award.

Dr. Harkany's early contributions addressed the developmental dynamics of endocannabinoid signalling; particularly showing that endocannabinoid action on cannabinoid receptors affects neuronal migration and differentiation in the cerebral cortex (PNAS, 2005/2008; J Neurosi 2010; Nat Commun 2014). He has demonstrated that endocannabinoids act as repulsive cues for directional axonal growth, thus being important to shape neuronal connectivity in the developing brain (Science, 2007). He then applied this knowledge to identify the nascent axon as the compartment foremost affected by THC action and described the molecular mechanism by which THC impairs cytoskeletal dynamics to inhibit axonal growth (EMBOJ, 2014).

Sumitomo/Sunovion Brain Health Clinical Research Award

Gustavo Turecki

Dr. Gustavo Turecki's research focuses on understanding the molecular changes that occur in the brains of individuals who feel so hopeless and depressed that they see suicide as the only way out. Gustavo's multidisciplinary career has focused on both the influence of life events of the risk of depression, suicide, and suicidal behaviour, and on the epigenetic control of brain function and development. He regularly publishes his work in the highest-ranked journals, including 20 articles in Nature and sister journals such as Nature Neuroscience, all since 2007. His productivity has earned him an h-index of 98, and his nearly 500 publications have collectively been cited over 36,000 times.

Gustavo is a recognized leader in the molecular and genomic aspects of suicide and depression. He is regularly invited to contribute review articles and position papers for leading clinical and scientific journals. These reviews, such as the ones published in Trends in Neuroscience (2012), in Nature Neuroscience Reviews (2014), Molecular Psychiatry (2017), or in Nature Reviews Disease Primers (2019) allow researchers to stay informed of recent molecular and biological advances related to suicide.

CINP 2020/21 Awardees

Ethics Prize

Paul Appelbaum

For the last decade, Dr. Paul Appelbaum has headed an NIH-funded center for studies of ethical, legal and social issues in neuropsychiatric and behavioral genetics at Columbia. He has identified many of the ethical challenges associated with advances in psychiatric genetics, the ethics and effects of research on genetic bases for addictions, the preferences of people with disabilities (including psychiatric disabilities) regarding inclusion in genomic research, and popular understandings of the genetic bases of antisocial behavior. He co-led a project on the ethics of genetic research on intelligence, and has written on return of research results, informed consent and other aspects of genetic research.

Dr. Appelbaum's prominence as a psychiatric ethicist has been recognized with his appointments as chair of the APA's Ethics Review Board, the WPA's Standing Committee on Ethics, and the ACNP Ethics Committee. He has received AMA's Award for Leadership in Medical Ethics and Professionalism, and a Special Presidential Commendation from the APA for his ethics leadership. His contributions have led to his election to the U.S. National Academy of Medicine and numerous named lectureships in medical ethics.

Max Hamilton Memorial Prize

Mu-Hong Chen

Dr. Mu-Hong Chen, M.D., Ph.D. graduated from Department of Medicine, National Yang-Ming University, Taiwan in 2006 and received his general psychiatric training between 2009 and 2013 and completed his child and adolescent psychiatric training in 2014.

His research career began in the first year (2009) of the resident training course and joined and completed the rTMS/TBS (theta burst stimulation) clinical trials (as the second author) for treatment-resistant depression (TRD) under Prof Tung-Ping Su's and Prof Cheng Ta Li's instructions.
For Dr Chen's research hard-working, he received WFSBP poster travel award in 2013, Taiwan- Japanese Young Scientist Award in 2014 and 2015, and Outstanding Research Award and Excellent Research Award for Asian College of Neuropsychopharmacology 2019. Dr Chen is also enthusiastic in the teaching and got the Clinical Teaching Excellence Physician Award, 2016, Taipei Veterans General Hospital.

Finally, Dr Chen is also a poet, won several literary awards, and published three poetries, including Sailor's diary, Quietness, and Gods and Monsters. He also works hard in LGBT mental health and promotes the LGBT psychoeducation for the medical students and psychiatrists.

CINP 2020/21 Awardees

Rafaelsen Young Investigators Awards

Lucie Bartova

Dr. Lucie Bartova, born in Ostrava, Czech Republic, obtained her medical degree (MD) in 2012 at the Medical University of Vienna (MUV) in Austria. As a diploma and subsequently doctoral student at the Department of Psychiatry and Psychotherapy of the MUV, she investigated neuroimaging correlates of acute and remitted major depressive disorder (MDD) and obtained her scientific degree (PhD) in 2019. Simultaneously, she completed her psychotherapeutic training and residency in psychiatry, whereby she has been involved in clinical, psychopharmacotherapeutic and neuroimaging studies focusing predominantly on MDD and schizophrenia. In the past years, Dr. Lucie Bartova has increasingly focused on challenging psychiatric conditions such as treatment resistant depression (TRD). She presented her work at national and international conferences which could be published in known psychiatric journals, received performance scholarship of the MUV as well as travel- and research awards, and served as a member of the Scientific Programme & Local Organising Committee for the CINP Thematic Meeting 2017 in Prague, Czech Republic on the topic of TRD.

Chandni Hindocha

Dr Chandni Hindocha graduated with a PhD in Psychopharmacology in 2018 from University College London (UCL). Her research focuses on the behavioural, neuroimaging and genetic risk factors that lead people to experience the acute and chronic effects of cannabis. She has 35 publications of which 15 are first-author papers. She has a strong background in clinical trials of highly-regulated investigative medicinal products, experimental and translational medicine using both longitudinal and cross-sectional research. Chandni is currently a post-doctoral research fellow at the Clinical Psychopharmacology Unit and the Translational Psychiatry Research Group, University College London.

Millie Rincón-Cortés

Millie Rincón-Cortés, PhD, is a Postdoctoral Research Associate in the laboratory of Dr. Anthony Grace at the University of Pittsburg. Here, she has been funded through aT32- Training for Transformative Discovery in Psychiatry Fellowship, an F32 Individual Postdoctoral Fellowship from the National Institute of Mental Health (NIMH) to study stress-induced dopamine downregulation in rats and how these effects may differ between the sexes, and a Ford Foundation Postdoctoral Fellowship to study how adverse postpartum environments influence maternal brain and behavior. Prior to joining the Grace lab, she received her B.S. in Biology from the University of Puerto Rico-Mayaguez (2009) before completing a PhD in Neuroscience and Physiology at the NYU Medical Center's Sacker Institute for Graduate Biomedical Sciences (2015). Her dissertation work was conducted under the supervision of Dr. Regina Sullivan and funded by a National Science Foundation (NSF) Graduate Research Fellowship. Dr. Rincón-Cortés was awarded the Sackler Dissertation Prize by the NYU School of Medicine and the Dissertation Award by the International Society for Developmental Psychobiology (ISDP) for this work.

CINP 2020/21 Awardees

Rafaelsen Young Investigators Awards (ctd)

Zachary Gerring

Zachary Gerring is a human geneticist specialising in the statistical analysis of common complex traits. His expertise spans statistical genetic and genomic analysis, epidemiology, bioinformatics and biostatistics. Zac is a postdoctoral fellow at the Queensland Institute of Medical Research Berghofer (QIMRB) in Australia, where, as a member of the psychiatric genomics consortium, he has made a substantial contribution to the functional analysis of neuropsychiatric disorders. Most notably, he developed a gene co-expression network-based analytical approach for the functional interpretation of genome-wide association data, as well as a gene-based method for the identification of candidate causal genes underlying complex traits. Zac is currently working on the integration of gene co-expression network data with a large database of drug-gene signatures to identify drug compounds that target dysfunctional mechanisms underlying Alzheimer's disease.

Pia Baldinger-Melich

After receiving her doctoral degree in 2009 (M.D.), Pia Baldinger-Melich joined the Neuroimaging Lab at the Department of Psychiatry and Psychotherapy at the Medical University of Vienna in April 2010 and was involved in the planning and implementation of several neuroimaging studies (using PET and MRI), especially with regard to mood and anxiety disorders. In 2015 she finish successfully the doctoral program "Clinical Neuroscience" (PhD) in the field of imaging genetics. In 2016 she became Assistant Professor and has since then dedicated her work on the search for imaging markers of depression and antidepressant treatments, including electroconvulsive therapy. Since 2018 Pia Baldinger-Melich is a senior physician at the Intermediate Care Unit of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna.

Giselli Scaini

Giselli Scaini received her PharmD degree (2008), a master's degree (2010), and her PhD (2014), in Health Science from the University of Southern Santa Catarina (UNESC, Brazil). Currently, she is an instructor at the Faillace Department of Psychiatry and Behavioral Sciences and a translational researcher in the field of biological psychiatry. Scaini's translational research is focused on understanding the complex interactions between molecular and cellular mechanisms and cognitive impairment, behavioral, and neuroanatomical changes in psychiatry disorders, especially in mood disorders.

Hon-Cheon So

Hon-Cheon So is a physician-scientist who was trained both clinical medicine and statistical genomics. He was enrolled in the first intercalated MBBS-PhD program in Hong Kong and received his graduate education in statistical and psychiatric genomics.

His main research interest lies in the development and applications of statistical and computational methodologies in analyzing "omics" and clinical data, with a special interest in psychiatry. For example, together with colleagues, they have developed methods to decipher the genetic architecture of complex diseases, performed risk prediction and subtyping of psychiatric disorders by both clinical and genomic data, and repositioned existing drug for new indications in psychiatry. The over-arching goal is to translate genomics findings into clinical practice, with the hope to improve diagnosis and treatment of complex diseases.

CINP 2020/21 Awardees

Student Encouragement Awards

Yui Asaoka, Japan

Yee-Lam Elim Chan, Taiwan

Chun-Hung Chang, Taiwan

Hsuan-Te Chu, Taiwan

Tomonori Hara, Japan

Cassandra Jay Hatzipantelis, Australia

Mao-Hsuan Huang, Taiwan

Arkadiusz Komorowski, Austria

Aika Kosuge, Japan

Hisayoshi Kubota, Japan

Shunya Kurokawa, Japan

Yuka Kusui, Japan

Chi-Wei Lee, Taiwan

Da-Zhong Luo, Taiwan

Hajime Miyanishi, Japan

Youge Qu, Japan

Joep Titulaer, Sweden

Shih-Chun Wan, Taiwan

Siming Wang, Japan

Ana Weidenauer, Austria

Registration



Registration Rates

Early Rates	Early Registration Ends 15 December 2020	Late Registration After 15 December 2020
CINP Member*	USD 275.00	USD 375.00
CINP Non-Member*	USD 375.00	USD 475.00
Low Resource Country CINP Member**	USD 125.00	USD 225.00
Low Resource Country CINP Non-Member**	USD 175.00	USD 275.00
Young Scientist CINP Member*** (35 years or younger in 2021)	USD 100.00	USD 200.00
Young Scientist CINP Non-Member*** (35 years or younger in 2021)	USD 150.00	USD 250.00
Student/Trainee CINP Member****	USD 50.00	USD 75.00
Student/Trainee CINP Non-Member****	USD 75.00	USD 100.00

*CINP membership number is required during the online registration process. If you do not know your membership number, please contact info@cinp.org.
**Low Resource Country List is available by clicking here.
***Young Scientists are required to provide official photo identification with date of birth during the online registration process.
****Proof of Status is required during the online registration process. Please provide a student card with photo or an official letter on your institution's/organization's letterhead that indicates proof of status as a Student or Trainee. If you are also a CINP Member, you will be required to provide your CINP membership number. If you do not know your membership number, please contact info@cinp.org.

Registration Includes:

- Access to all live and on-demand content
- Access to the Virtual Posters
- Access to the Industry Exhibit Hall
- Networking Breaks with Colleagues
- Certificates of Attendance

Further Information

For more information, please visit the official Congress website www.virtual.cinp2021.org/registration. For any inquiries regarding registration for the CINP 2021 Virtual World Congress, please contact CINP2021-registration@cinp.org

Sponsorship & Exhibit Opportunities

Please contact our dedicated **CINP Sponsorship and Exhibit Sales Manager**, Shalini Padman, at sponsorship@cinp.org for more information on our sponsorship and exhibit options, and to start discussing how you would like to support, and be involved at the **CINP 2021 Virtual World Congress**. We are looking forward to discussing other novel and innovative sponsorship opportunities that you might like to suggest or explore.

Exclusive Available on Demand

Industry-Supported Symposium **USD 50,000**	Virtual Seminar **USD 20,000**
Initial Registration Confirmation Email **USD 5,000**	Virtual Bag Insert **USD 3,000**
Pre-Congress E-Blast **USD 2,000**	Virtual Booth **USD 2,500**
Final Registration Confirmation Email **USD 8,000**	Website Banner Ad (1 month) **USD 1,500**
Promotional Video on Website **USD 2,500**	

Awards

Max Hamilton Memorial Prize **USD 15,000**	Pioneer in Psychopharmacology Award **USD 15,000**
CINP 32nd World Congress Student Encouragement Award **USD 6,000**	Rafaelsen Young Investigators Award **USD 5,000**



CINP

CINP Head Office

Gonzagagasse 17
1010 Vienna
Austria

Phone: +43 660 1258 463
Fax: +1 604 681 1049
info@cinp.org | **www.cinp.org**

For further information on CINP and to keep up to date with all CINP activities please visit www.cinp.org